Cipla: India Strength & Global Pharma Recovery

Cipla remains a leading pharmaceutical company with strong franchises in respiratory, chronic therapies, generics and emerging markets. Q1 FY27 revenue rose 2.3% YoY to ₹7,119 crore, while PAT declined 39.2% to ₹789 crore, mainly due to a high North America base and weaker contribution from key products. Latest News: India revenue reached a record ₹3,452 crore, up 12% YoY, supported by respiratory, diabetes and cardiac therapies. North America revenue fell 21%, weighing on margins. Corporate Action/Catalysts: Cipla is expanding its obesity-treatment portfolio through an Eli Lilly licensing deal, while new US launches and respiratory products could support recovery. However, regulatory issues remain a concern: Maharashtra FDA recently cancelled sale licences at its Pune C&F facility following compliance lapses.